Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study

References

• Warner RR. Enteroendocrine tumors other than carcinoid: a review of clinically significant advances. Gastroenterology. 2005;128:1668–1684.
   PubMed Web of Science ®Google Scholar
• Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–1342.
   PubMed Web of Science ®Google Scholar
• Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61–72.
   PubMed Web of Science ®Google Scholar
• Soga J. Carcinoids and their variant endocrinomas. An analysis of 11842 reported cases. J Exp Clin Cancer Res. 2003;22:517–530.
   PubMed Web of Science ®Google Scholar
• Tomassetti P, Migliori M, Lalli S, et al. Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours. Ann Oncol. 2001;12:S95–S99.
   PubMed Web of Science ®Google Scholar
• Halperin DM, Shen C, Dasari A, et al. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study. Lancet Oncol. 2017;18:525–534.
   PubMed Web of Science ®Google Scholar
• Dimitriadis GK, Weickert MO, Randeva HS, et al. Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer. 2016;23:R423–R436.
   PubMed Web of Science ®Google Scholar
• Grozinsky-Glasberg S, Grossman AB, Gross DJ. Carcinoid heart disease: from pathophysiology to treatment – 'something in the way it moves'. Neuroendocrinology. 2015;101:263–273.
   PubMed Web of Science ®Google Scholar
• Davar J, Connolly HM, Caplin ME, et al. Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement. J Am Coll Cardiol. 2017;69:1288–1304.
   PubMed Web of Science ®Google Scholar
• Faiss S, Pape UF, Bohmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors – the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003;21:2689–2696.
   PubMed Web of Science ®Google Scholar
• Broder MS, Beenhouwer D, Strosberg JR, et al. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review. World J Gastroenterol. 2015;21:1945–1955.
   PubMed Web of Science ®Google Scholar
• Khan MS, El-Khouly F, Davies P, et al. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel). Aliment Pharmacol Ther. 2011;34:235–242.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Neuroendocrine Tumors. NCCN Clinical Practice Guidelines in Oncology. 2017 [cited Sep 2017]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf.
   Google Scholar
• Strosberg J, Weber J, Feldman M, et al. Above-label doses of octreotide-LAR in patients with metastatic small intestinal carcinoid tumors. Gastrointest Cancer Res. 2013;6:81–85.
   PubMedGoogle Scholar
• Strosberg JR, Benson AB, Huynh L, et al. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist. 2014;19:930–936.
   PubMed Web of Science ®Google Scholar
• Weber JM, Feldman M, Kvols L, et al. Above-label doses of octreotide-LAR in patients with metastatic small-intestinal carcinoid tumors. J Clin Oncol. 2012;30:e14579.
   Web of Science ®Google Scholar
• Pavel M, O’Toole D, Costa F, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103:172–185.
   PubMed Web of Science ®Google Scholar
• Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15:966–973.
   PubMed Web of Science ®Google Scholar
• de Herder WW. When and how to use somatostatin analogues. Endocrinol Metab Clin North Am. 2018;47:549–555.
   PubMed Web of Science ®Google Scholar
• Pavel M, Baudin E, Couvelard A, et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157–176.
   PubMed Web of Science ®Google Scholar
• Kulke MH, O'Dorisio T, Phan A, et al. Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer. 2014;21:705–714.
   PubMed Web of Science ®Google Scholar
• Ayyagari R, Neary M, Li S, et al. Comparing the cost of treatment with octreotide long-acting release versus lanreotide in patients with metastatic gastrointestinal neuroendocrine tumors. Am Health Drug Benefits. 2017;10:408–415.
   PubMed Web of Science ®Google Scholar
• Ortendahl JD, Pulgar SJ, Mirakhur B, et al. Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals. ClinicoEconomics and Outcomes Research: CEOR. 2017;9:495–503.
   PubMed Web of Science ®Google Scholar
• Budget impact of somatostatin analogs (SSAs) as treatment for metastatic gastroenteropancreatic neuroendocrine tumors (mGEP-NETs) in US hospitals. Clin Adv Hematol Oncol. 2016;14:10–11.
   Web of Science ®Google Scholar
• Broder MS, Cai B, Chang E, et al. First-line systemic treatment adherence, healthcare resource utilization, and costs in patients with gastrointestinal neuroendocrine tumors (GI NETs) in the USA. J Med Econom. 2018;21:821–826.
   PubMed Web of Science ®Google Scholar
• Joish VN, Frech F, Lapuerta P. Budgetary impact of telotristat ethyl, a novel treatment for patients with carcinoid syndrome diarrhea: a US health plan perspective. Clin Ther. 2017;39:2338–2344.
   PubMed Web of Science ®Google Scholar
• Joish VN, Frech F, Lapuerta P. Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs. J Med Econom. 2018;21:182–188.
   PubMed Web of Science ®Google Scholar
• Riechelmann RP, Pereira AA, Rego JFM, et al. Refractory carcinoid syndrome: a review of treatment options. Ther Adv Med Oncol. 2017;9:127–137.
   PubMed Web of Science ®Google Scholar
• Rinke A, Müller H-H, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27:4656–4663.
   PubMed Web of Science ®Google Scholar
• Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224–233.
   PubMed Web of Science ®Google Scholar
• Zandee WT, de Herder WW. The evolution of neuroendocrine tumor treatment reflected by ENETS guidelines. Neuroendocrinology. 2018;106:357–365.
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology. 2016;103:186–194.
   PubMed Web of Science ®Google Scholar
• ICD.Codes: ICD-10-CM Code K59.1 [cited March 2018]. Available from: https://icd.codes/icd10cm/K591
   Google Scholar